How urolithin A may help reverse heart aging
Mechanisms underlying reversal of cardiac aging by urolithin a treatment
This study is looking at how a compound called urolithin A might help improve heart health and function as we get older, especially for older adults who may be facing heart-related issues.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10877344 on NIH RePORTER |
What this research studies
This research investigates the effects of urolithin A on reversing the aging process in the heart. It focuses on understanding how this compound can improve mitochondrial function, which is crucial for maintaining healthy heart performance as we age. The study will involve assessing cardiac function and cellular dynamics in older adults to determine if urolithin A can mitigate age-related cardiovascular issues. Patients may be monitored for changes in heart muscle cells and overall cardiovascular health.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults over 21 years old who are experiencing age-related cardiovascular decline.
Not a fit: Patients with pre-existing severe cardiovascular conditions or those under 21 years old may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve heart health and reduce the risk of cardiovascular diseases in older adults.
How similar studies have performed: Previous research has shown promising results with mitochondrial-targeted therapies in improving heart function in aging populations.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Marcinek, David J. — University of Washington
- Study coordinator: Marcinek, David J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.